| Name | Title | Contact Details |
|---|
Sucampo Pharmaceuticals, Inc. is focused on the development and commercialization of medicines that meet major unmet medical needs of patients worldwide. Sucampo has two marketed products – AMITIZA, its lead product, and RESCULA. A global company, Sucampo is headquartered in Rockville, Maryland, and has operations in Japan, Switzerland and the U.K. The Sucampo logo and the tagline, The Science of Innovation, are registered trademarks of Sucampo AG. AMITIZA is a registered trademark of Sucampo AG.
AEG Vision supports and empowers eyecare professionals to grow their practices while elevating focus on delivering excellent eyecare.
Trevi Therapeutics, Inc. is a late-stage clinical development company developing Nalbuphine® ER for chronic pruritus (itch). Pruritus develops in various dermatologic, metabolic, hematologic, and neuropathic conditions. The Company is pursuing two conditions for clinical development: uremic pruritus and prurigo nodularis. Uremic pruritus is a persistent and debilitating itch in patients on dialysis that has been associated with significant impairment in quality of life and increased mortality. Prurigo nodularis is an intensely pruritic dermatologic condition characterized by unsightly and itchy skin papules and nodules. There are no approved therapies in the United States or Europe for either condition.
Let’s operate. We prioritize you, so you can prioritize patients. Trusted brands like Quill, Sharpoint, and Tachosil.
IM Cannabis (IMC) is one of the world`s pioneering medical-grade cannabis companies, with operations in Israel, across Europe, and Canada. Over the past decade, IMC has established its premium medical cannabis brand, comprising a full spectrum of products known for their quality, consistency, and purity, such as ROMA, TEL AVIV and LONDON. In Europe, IMC has established a fully operational, vertically integrated medical cannabis business, spearheaded by its EU-GMP certified distribution arm in Germany and augmented by strategic alliances with certified pan-EUGMP certified suppliers. To this end, IMC has formed strong strategic alliances within the international medical cannabis industry, aiming for a dominant position in satisfying the global demand for high-quality medical cannabis products, which both physicians and patients can rely upon. IMC further intends to leverage its expertise in Israel in order to bolster its research and development initiative while collaborating with world-renowned scientists on cutting-edge technology for the benefit of patients around the world